534
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Conjugation of Functionalized Gadolinium Metallofullerenes with IL-13 Peptides for Targeting and Imaging Glial Tumors

, , , , , , , , , , , , & show all
Pages 449-458 | Published online: 04 May 2011

Bibliography

  • Kumar HR , ZongX, SandovalJA, HickeyRJ, MalkasLH: Applications of emerging molecular technologies in glioblastoma multiforme.Expert Rev. Neurother.8, 1497–1506 (2008).
  • Shu CY , ZhangEY, XiangJFet al. Aggregation studies of the water-soluble gadofullerene magnetic resonance imaging contrast agent: [Gd@C82O6(OH)16 (NHCH2CH2COOH)8]x. J. Phys. Chem. B 110, 15597–15601 (2006).
  • Shu CY , GanLH, WangCR, PeiXL, HanHB: Synthesis and characterization of a new water-soluble endohedral metallofullerene for MRI contrast agents.Carbon44, 496–500 (2006).
  • Fatouros PP , CorwinFD, ChenZJet al.: In vitro and in vivo imaging studies of a new endohedral metallofullerene nanoparticle.Radiology240, 756–764 (2006).
  • Toth E , BolskarRD, BorelAet al.: Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents.J. Am. Chem. Soc.127, 799–805 (2005).
  • Sitharaman B , BolskarRD, RusakovaI, WilsonLJ: Gd@C60[C(COOH)2]10 and Gd@C60(OH)x: nanoscale aggregation studies of two metallofullerene MRI contrast agents in aqueous solution.Nano Lett.4, 2373–2378 (2004).
  • Kato H , KanazawaY, OkumuraMet al.: Lanthanoid endohedral metallofullerenols for MRI contrast agents.J. Am. Chem. Soc.125, 4391–4397 (2003).
  • Bolskar RD , BenedettoAF, HuseboLOet al.: First soluble M@C60 derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C60[C(COOH)2]10 as a MRI contrast agent.J. Am. Chem. Soc.125, 5471–5478 (2003).
  • Mikawa M , KatoH, OkumuraMet al.: Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents.Bioconjugate Chem.12, 510–514 (2001).
  • Shu CY , CorwinFD, ZhangJet al.: Facile preparation of a new gadofullerene-based magnetic resonance imaging contrast agent with high H-1 relaxivity.Bioconjugate Chem.20, 1186–1193 (2009).
  • Shu CY , WangC, ZhangJet al.: Organophosphonate functionalized Gd@C-82 as a magnetic resonance imaging contrast agent.Chem. Mater.20, 2106–2109 (2008).
  • Shu CY , MaXY, ZhangJFet al.: Conjugation of a water-soluble gadolinium endohedral fulleride with an antibody as a magnetic resonance imaging contrast agent.Bioconjugate Chem.19, 651–655 (2008).
  • MacFarland DK , WalkerKL, LenkRPet al.: Hydrochalarones: a novel endohedral metallofullerene platform for enhancing magnetic resonance imaging contrast.J. Med. Chem.51, 3681–3683 (2008).
  • Zhang EY , ShuCY, FengL, WangCR: Preparation and characterization of two new water-soluble endohedral metallofullerenes as magnetic resonance imaging contrast agents.J. Phys. Chem. B111, 14223–14226 (2007).
  • Shultz MD , DuchampJC, WilsonJDet al.: Remotely controlled encapsulation of a radiolabeled cluster inside a fullerene cage, 177Lu(3-x)N@C80: an interleukin-13-conjugated radiolabeled metallofullerene platform.J. Am. Chem. Soc.132, 4980–4981 (2010).
  • Debinski W , ObiriNI, PowersSK, PastanI, PuriRK: Human glioma cells over express receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin.Clin. Cancer Res.1, 1253–1258 (1995).
  • Debinski W , MinerR, LelandP, ObiriNI, PuriRK: Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells.J. Biol. Chem.271, 22428–22433 (1996).
  • Debinski W , GiboDM, HuletSW, ConnorJR, GillespieGY: Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.Clin. Cancer Res.5, 985–990 (1999).
  • Mintz A , GiboDM, Slagle-WebbB, ChristensenND, DebinskiW: IL-13Rα2 is a glioma-restricted receptor for interleukin-13.Neoplasia4, 388–399 (2002).
  • Lupardus PJ , BirnbaumME, GarciaKC: Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Rα2.Cell18, 332–342 (2010).
  • Lazovic J , JensenMC, FerkassianEet al.: Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.Clin. Cancer Res.14, 3832–3839 (2008)
  • Kawakami K , TerabeM, KioiM, BerzofskyJA, PuriRK: Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13α2-expressing contralateral tumors.Clin. Cancer Res.12, 4678–4686 (2006).
  • Kunwar S , AkabaniGE, ArcherGEet al.: Direct intracerebral delivery of cintredekin besudotox (IL-13–PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.J. Clin. Oncol.25, 837–844 (2007).
  • Madhankumar AB : Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model.Mol. Cancer Ther.8, 648–654 (2009).
  • Bernardi RJ , LoweryAR, ThompsonPA, BlaneySM, WestJL: Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines.J. Neurooncol.86, 165–172 (2008).
  • Madhankumar AB , MintzA, DebinskiW: Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Rα2.Neoplasia6, 15–22 (2004).
  • Chen Z-J , Gillies GT, Broaddus WC et al.: A realistic brain tissue phantom for intraparenchymal infusion studies. J. Neurosurg.101, 314–322 (2004).
  • Yuguo L , XiaodongZ, QingnuanL, WenxinL: Radioiodination of C60 derivative C60(OH)xOy.J. Radioan. Nucl. Ch.250, 363 (2001).
  • Stevenson S , RiceG, GlassTet al.: Small-bandgap endohedral metallofullerenes in high yield and purity.Nature401, 55–57 (1999).
  • Qian M , OngSV, KhannaSN, KnickelbeinMB: Magnetic endohedral metallofullerenes with floppy interiors.Phys. Rev. B75, 1–6 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.